sc13dza

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1 )*

Replidyne, Inc.

(Name of Issuer)

Common Stock, $0.001

(Title of Class of Securities)

76028W-107

(CUSIP Number)

Laurence L. Betterley
Cardiovascular Systems, Inc.
651 Campus Drive
St. Paul, MN 55112
(877) 274-0360

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

December 19, 2008

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D


CUSIP No.		76028W-107		Page		2		of		5 Pages

NAMES OF REPORTING PERSONS

Cardiovascular Systems, Inc.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)*

(a) o

(b) o

SEC USE ONLY

SOURCE OF FUNDS (SEE INSTRUCTIONS)

OO (See Item 3)

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

SOLE VOTING POWER

NUMBER OF

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,789,801 shares of Common Stock (See Items 4 and 5)

EACH

SOLE DISPOSITIVE POWER

REPORTING

PERSON

WITH

SHARED DISPOSITIVE POWER

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,789,801 shares of Common Stock

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

32.4% shares of Common Stock*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

* Calculated based on 27,109,545 shares outstanding at November 3, 2008, as represented by Replidyne in the Merger Agreement described in Item 3.

Explanatory Note : This Amendment No. 1 relates to and amends the Statement of Beneficial Ownership on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2008 (the “Statement”) by Cardiovascular Systems, Inc. (“CSI”) with respect to the common stock, $0.001 par value per share, of Replidyne, Inc., a Delaware corporation (“Replidyne”).

Items 3, 4 and 5 of the Statement are hereby amended to the extent hereinafter expressly set forth. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement.

Item 3. Source and Amount of Funds or Other Consideration

Since the date of the Statement, on December 18, 2008, CSI released the Shares owned by HealthCare Investment Partners Holdings II LLC from the Voting Agreements. As a result, the Voting Agreement Stockholders, together with their respective affiliates, beneficially own approximately 47.7% of the outstanding common stock of Replidyne, and approximately 32.4% of the outstanding common stock of Replidyne is subject to the voting requirements set forth in the Voting Agreements and the Irrevocable Proxies.

Item 4. Purpose of Transaction

The names of the Voting Agreement Stockholders and the number of shares of Replidyne’s common stock and the percentage ownership that are subject to the Voting Agreements is set forth in Schedule B hereto which is hereby incorporated by reference.

Item 5. Interest in Securities of the Issuer

As a result and subject to the terms of the Voting Agreements and the Irrevocable Proxies granted pursuant thereto, CSI may be deemed to have the power to vote an aggregate of 8,789,801 shares of Replidyne’s common stock, in each case for the limited purposes described in Item 4 of the Statement. Such shares constitute approximately 32.4% of the issued and outstanding shares of Replidyne’s common stock based on the number of shares outstanding at November 3, 2008. Other than with respect to the voting rights granted to CSI pursuant to the Voting Agreements and the Irrevocable Proxies, CSI does not have the right to vote such shares on any other matters. CSI shares such voting power with the executives of CSI identified in the Irrevocable Proxies. CSI does not have any power to dispose or direct the disposition of any shares of Replidyne’s common stock.

Except as described herein, CSI has not effected any transaction in Replidyne’s common stock during the past 60 days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: December 31, 2008	CARDIOVASCULAR SYSTEMS, INC.
	By:	/s/ James E. Flaherty
		James E. Flaherty
		Chief Administrative Officer and Secretary

4484265

SCHEDULE B

VOTING AGREEMENT STOCKHOLDERS


	Replidyne Common Stock Subject to Voting
	Agreement
Name of Voting Agreement Stockholder	Number of Shares		Percentage Ownership

Kenneth J. Collins		360,520		1.3	%
TPG Biotechnology Partners, L.P.; TPG Ventures, L.P.		1,871,982		6.9	%
HealthCare Ventures VI, L.P.; HealthCare Ventures VIII, L.P.		2,964,167		10.9	%
Sequel Limited Partnership III; Sequel Entrepreneurs’ Fund III, L.P.		986,887		3.6	%
The Daniel J. Mitchell Trust		11,336		*
Morgenthaler Partners VII, L.P.		1,583,200		5.8	%
Perseus-Soros Biopharmaceutical Fund, LP		1,011,709		3.7	%


*		Less than 1% of the outstanding share